KEIO RESEARCHERS INFORMATION SYSTEM

Career 【 Display / hide 】

Career 【 Display / hide 】

• 2003.04

  -

  2007.03

  鹿児島大学医学部・歯学部附属病院, 薬剤部, 医療職員

• 2007.04

  -

  2014.03

  鹿児島大学医学部・歯学部附属病院, 薬剤部, 主任

• 2014.04

  -

  2017.03

  慶應義塾大学薬学部, 実務薬学講座, 准教授

• 2017.04

  -

  Present

  慶應義塾大学薬学部, 薬効解析学講座, 教授

Academic Background 【 Display / hide 】

Academic Background 【 Display / hide 】

• 1994.04

  -

  1998.03

  Kumamoto University, 薬学部, 薬学科

  University, Graduated

• 1998.04

  -

  2000.03

  Kumamoto University, 薬学研究科

  Graduate School, Completed, Master's course

• 2000.04

  -

  2003.03

  Kumamoto University, 薬学研究科

  Graduate School, Completed, Doctoral course

Academic Degrees 【 Display / hide 】

Academic Degrees 【 Display / hide 】

• 博士（薬学）, Kumamoto University, Coursework, 2003.03

  α1-酸性糖蛋白質の生理作用と動態特性に関する研究

Licenses and Qualifications 【 Display / hide 】

Licenses and Qualifications 【 Display / hide 】

• 薬剤師免許証, 1998.07

• 日本薬剤師研修センター認定薬剤師, 2006.03

• 日本医療薬学会認定薬剤師, 2009.01

• インフェクションコントロールドクター, 2009.01

• 感染制御専門薬剤師, 2009.03

display all >>

Research Areas 【 Display / hide 】

Research Areas 【 Display / hide 】

• Life Science / Clinical pharmacy

Research Keywords 【 Display / hide 】

Research Keywords 【 Display / hide 】

• Pharmacokinetics/Pharmacodynamics

• Therapeutic drug monitoring

• 抗菌化学療法

• 高齢者医療

Research Themes 【 Display / hide 】

Research Themes 【 Display / hide 】

• 医薬品の薬効評価と副作用解析に基づいた薬物療法の最適化に関する研究, 

  2014.04

  -

  Present

Books 【 Display / hide 】

Books 【 Display / hide 】

• 今日の治療薬2026

  松元一明, 南江堂, 2026.01

• 今日の治療指針2026

  松元一明, 医学書院, 2026.01

  Scope: 市中肺炎/疥癬, アタマジラミ症/急性中耳炎　服薬指導・薬剤情報

• 感染症学

  松元一明, 南山堂, 2025.02,  Page： 222-236

  Scope: 中枢神経系感染症.

• 今日の治療薬2025

  松元一明, 南江堂, 2025.01

• 今日の治療指針2025

  松元一明, 医学書院, 2025.01

  Scope: 市中肺炎/急性中耳炎 服薬指導・薬剤情報

display all >>

Papers 【 Display / hide 】

Papers 【 Display / hide 】

• Age and body weight-adjusted infusion rate (mg/kg/h) as risk factors for vancomycin infusion reaction in patients receiving perioperative antimicrobial prophylaxis: a retrospective cohort study.

  Iketani O, Uno S, Shinjoh M, Takemura R, Fukuda S, Seyama S, Kimura M, Ishikawa H, Hayakawa T, Uwamino Y, Namkoong H, Yoshifuji A, Obara H, Takano Y, Enoki Y, Taguchi K, Sato Y, Matsumoto K, Hasegawa N

  JAC-antimicrobial resistance 8 ( 3 ) dlag084 2026.06

  Joint Work

  • Access to Document (DOI)

• Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial.

  Takahashi S, Tateda K, Yanagihara K, Huang H, Doi Y, Yasuda M, Matsumoto K, Sumiya M, Takaya R, Suwada K, Kamiyabu S, Sasagawa Y, Minamida T, Kato S, Kondo K, Naruse T, Mikamo H

  Lancet (London, England) 407 ( 10542 ) 1929 - 1940 2026.05

  Joint Work,  ISSN  0140-6736

  　View Summary

  Background Nacubactam (OP0595) is a newly developed diazabicyclooctane β-lactamase inhibitor used in combination with cefepime or aztreonam. We assessed the efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam versus imipenem–cilastatin in complicated urinary tract infection (cUTI) or acute uncomplicated pyelonephritis. Methods The Integral-1 global, phase 3, multicentre, randomised, double-blind study recruited adults (aged ≥18 years) with cUTI or acute uncomplicated pyelonephritis at 79 sites in Bulgaria, China, Czech Republic, Estonia, Georgia, Japan, Latvia, Lithuania, and Slovakia. Patients were randomly assigned (2:1:1) to receive intravenous cefepime (2 g) plus nacubactam (1 g), aztreonam (2 g) plus nacubactam (1 g), or imipenem (1 g) plus cilastatin (1 g) every 8 h for 5–14 days. Randomisation was stratified by diagnosis and geographical region. The primary endpoint was the proportion of patients achieving composite clinical and microbiological success at test of cure in the microbiological modified intention-to-treat population—all patients who were randomly assigned, received any amount of the study drug, and had a baseline qualifying pathogen that was susceptible to imipenem and meropenem. The prespecified non-inferiority margin was more than 15 percentage points difference; the superiority margin was more than zero percentage points difference, for the lower bound of the two-sided 95% CI for imipenem–cilastatin. Safety was assessed in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov , NCT05887908 . Findings Between May 22, 2023, and Nov 26, 2024, 614 patients were randomly assigned and 431 were included in the primary efficacy analysis (cefepime–nacubactam [n=214], aztreonam–nacubactam [n=112], or imipenem–cilastatin [n=105]); 228 patients (53%) were male and 203 (47%) were female. The primary endpoint was achieved by 176 (82%) of 214, 81 (72%) of 112, and 64 (61%) of 105 patients in the cefepime–nacubactam, aztreonam–nacubactam, and imipenem–cilastatin groups, respectively. The percentage difference in the success rate versus imipenem–cilastatin was 21·3% (95% CI 10·9 to 32·0) for cefepime–nacubactam (non-inferior and superior), and 11·4% (−1·2 to 23·7) for aztreonam–nacubactam (non-inferior). Treatment-emergent adverse events were reported in 100 (33%) of 306, 45 (30%) of 152, and 65 (43%) of 150 patients in the cefepime–nacubactam, aztreonam–nacubactam, and imipenem–cilastatin groups, respectively. No treatment-related deaths occurred. Interpretation Cefepime–nacubactam and aztreonam–nacubactam are potential treatment options for Gram-negative cUTI and acute uncomplicated pyelonephritis, including infections caused by antimicrobial-resistant strains. Funding Meiji Seika Pharma and Japan Agency for Medical Research and Development.

  • Access to Document (DOI)

• Practical dose ranges supporting target vancomycin exposure with AUC-guided dosing in overweight and obese patients: A multicentre retrospective study.

  Endo A, Hanai Y, Namiki T, Hanawa K, Hashi H, Asakawa D, Yokoyama Y, Maruyama R, Tsujimura S, Igarashi Y, Enoki Y, Matsumoto K, Matsumoto K

  British journal of clinical pharmacology  2026.05

  Joint Work,  ISSN  0306-5251

  　View Summary

  Aim: Evidence supporting area under the concentration–time curve (AUC)–guided vancomycin dosing in overweight and obese patients remains limited. This multicentre retrospective study aimed to identify pragmatic loading dose (LD) and maintenance dose (MD) ranges associated with target AUC attainment in this population. Methods: Patients aged ≥15 years with a body mass index (BMI) ≥ 25 kg/m² who received vancomycin for ≥3 days and had ≥2 trough concentration measurements were included from four Japanese hospitals (2012–2025). AUC<inf>0–24</inf> and steady-state AUC<inf>24</inf> (AUC<inf>ss</inf>) were estimated using Bayesian software. Multivariate logistic regression analyses identified factors associated with achieving target AUCs (AUC<inf>0–24</inf>: 400–500 μg·h/mL; AUC<inf>ss</inf>: 400–600 μg·h/mL). Results: Among 209 patients (median BMI 27.2 kg/m²), LD was independently associated with attainment of target AUC<inf>0–24</inf> (OR 1.08, 95% CI 1.02–1.15). An LD of approximately 20 mg/kg was associated with early target exposure. For maintenance therapy, estimated glomerular filtration rate (eGFR) and MD were independently associated with AUC<inf>ss</inf> attainment (OR 0.979, 95% CI 0.964–0.995, p = 0.008; OR 1.050, 95% CI 1.010–1.090, p = 0.018, respectively). Pragmatic interim MD ranges were approximately 9.2, 16.2 and 26.3 mg/kg/day for patients with eGFR<30, 30–60 and >60 mL/min/1.73 m², respectively. Conclusion: In this multicentre real-world cohort of overweight/obese adults, an LD around 20 mg/kg (ceiling 2 g) was associated with early AUC<inf>0–24</inf> target attainment. MD and renal function were independent predictors of AUC<inf>ss</inf>, informing interim renal-stratified MD ranges until TDM results become available. Early TDM remains essential given significant inter-individual variability.

  • Access to Document (DOI)

• Comparison of area under the concentration-time curve estimations between Practical Antimicrobial Therapeutic Drug Monitoring (PAT) versions 3 and 4 for vancomycin using two-point sampling.

  Suzuki A, Fujihara H, Yamaguchi F, Yoshida H, Tanaka H, Ishigo T, Fujii S, Ebihara F, Maruyama T, Yagi Y, Hamada Y, Nagumo F, Samura M, Komatsu T, Tomizawa A, Chiba H, Takuma A, Nishi Y, Igarashi Y, Enoki Y, Matsumoto K

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 32 ( 7 ) 102990 2026.05

  Joint Work,  ISSN  1341-321X

  　View Summary

  Practical Antimicrobial Therapeutic Drug Monitoring (PAT) for vancomycin using Bayesian estimation is recommended for calculating the area under the concentration–time curve (AUC). In 2025, PAT was updated from version 3 to version 4, but differences in AUC estimations between these versions have not been examined. This study aimed to compare AUC estimations from both versions in the same patients.We conducted a multicenter, retrospective, observational study involving adult patients who received vancomycin treatment between September 2020 and December 2023, who underwent two-point sampling for initial TDM. AUC was calculated using both versions in three phases: 0–24 h (AUC<inf>0–24</inf>), 24–48 h (AUC<inf>24–48</inf>), and at steady state (AUC<inf>ss</inf>).The sample included 894 cases. AUC values from versions 3 and 4 showed a high correlation (r = 0.947–0.964), but phase-related differences emerged. Version 4 yielded significantly lower AUC<inf>0–24</inf> and AUC<inf>24–48</inf> values (median: 420.7 μg h/mL vs 373.5 μg h/mL, p < 0.001; 398.9 μg h/mL vs 379.8 μg h/mL, p < 0.001), while AUC<inf>ss</inf> was significantly higher in version 4 (448.4 μg h/mL vs 498.2 μg h/mL, p < 0.001).Since differences in population pharmacokinetic models can affect estimation results, clinicians should be aware that AUC estimations may vary depending on the PAT version used, and the results should be interpreted with caution.

  • Access to Document (DOI)

• Establishing an assay to evaluate d-amino acid oxidase enzyme kinetics and inhibition using WST-8 redox dye.

  Miyake K, Enoki Y, Nakazawa Y, Taguchi K, Matsumoto K

  FEBS open bio  2026.02

  Joint Work

  　View Summary

  d-Amino acid oxidase (DAO) inhibitors are novel candidate therapeutic agents for neurodegenerative diseases. In this study, a novel inhibition assay using WST-8 as a detection reagent was developed and its effectiveness for evaluating redox-based enzyme kinetics was tested. Furthermore, using this assay, we also investigated the inhibitory activities of uremic toxins and endogenous amino acid metabolites. Briefly, a mixture of DAO, WST-8, and d-amino acids was allowed to react in phosphate buffer and DAO activity was detected as an increase in absorbance when both d-serine and DAO were present. However, as reducing compounds could potentially cause false-positive results, we confirmed that the detection of DAO activity in this system was mediated by the redox reaction of WST-8. Critically, we verified that this assay could be used to evaluate the inhibitory activity of known DAO inhibitors, including uremic toxins which showed weak DAO inhibition. This study establishes an alternative assay system that can be utilized for assessing DAO-inhibitory activity and other enzymatic reactions mediated by redox reactions.

  • Access to Document (DOI)

display all >>

Papers, etc., Registered in KOARA 【 Display / hide 】

Papers, etc., Registered in KOARA 【 Display / hide 】

• In vitro PK/PD evaluation for rapid development of therapeutic drugs for IMP-type MBL-producing bacterial infections

  Matsumoto, Kazuaki

  学事振興資金研究成果実績報告書 (慶應義塾大学)  2022

• Development of novel in vivo PK/PD evaluation models against CDI and its application

  Matsumoto, Kazuaki

  福澤諭吉記念慶應義塾学事振興基金事業報告集 (福澤基金運営委員会)  2021

• Development of individually optimized dosing regimen for antimicrobial agents aiming at overcoming antimicrobial-resistant bacterial infections

  Matsumoto, Kazuaki

  科学研究費補助金研究成果報告書 2020

Reviews, Commentaries, etc. 【 Display / hide 】

Reviews, Commentaries, etc. 【 Display / hide 】

• 抗菌薬治療におけるPK/PD理論の応用と実践

  松元 一明

  医療関連感染 (東京医療保健大学大学院)  18 ( 1 ) 1 - 8 2025.12

  ISSN  2187-9028

  　View Summary

  濃度依存的に効果を示すアミノグリコシド系などの薬物は、Cpeakが高いほど効果が大きいため、1日1回投与が推奨される。一方、時間依存的に効果を示すβラクタム系などの薬物は、MIC以上の血中濃度を維持する時間が長いほど効果が高まる。そのため、投与回数を増やしたり、点滴時間を延長・持続投与したりすることが効果的であり、特に敗血症患者では治癒率の向上が示唆されている。バンコマイシンなどのAUC/MICに分類される薬物は、AUCとMICの比が効果に影響し、有効性と安全性の観点からAUC400-600μg・h/mLが目標とされる。薬物療法の成功には、患者ごとの腎機能や肝機能を正確に評価し、最適な投与量を設計することが不可欠である。腎機能障害患者では血清クレアチニンや血清シスタチンCを、肝機能障害患者ではChild-Pugh分類などを活用して、投与量を慎重に調整する必要がある。(著者抄録)

• COVID-19抗ウイルス薬の薬物間相互作用

  松元 一明

  内科総合誌Medical Practice ((株)文光堂)  42 ( 12 ) 1875 - 1879 2025.12

  ISSN  0910-1551

• 多剤耐性菌・真菌・抗酸菌を含む病原性細菌に対するMA-T水溶液の殺菌・消毒効果の評価

  島田 そら, 水上 雄貴, 榎木 裕紀, 田口 和明, 松元 一明

  日本集中治療医学会雑誌 ((一社)日本集中治療医学会)  32 ( Suppl.2 ) S600 - S600 2025.09

  ISSN  1340-7988

• 抗菌薬の持続投与を再考する

  松元 一明

  J-IDEO ((株)中外医学社)  9 ( 4 ) 516 - 524 2025.07

  ISSN  2432-7077

• 感染制御に現場から一言　抗菌薬適正使用における薬剤師の役割

  松元 一明

  感染と消毒 (サラヤ(株))  32 ( 1 ) 52 - 55 2025.05

  ISSN  1346-2326

  　View Summary

  抗菌薬適正使用における薬剤師の役割は,益々重要になってきている.また,その役割は働いている施設により異なる.感染症診断の支援から携わる場合,抗菌薬選択または投与量設計から関わる場合もある.いずれにせよ科学的根拠に基づいて実施すべきである.本項では抗菌薬選択,投与量設計としてPK/PD,TDMの考え方について述べる.(著者抄録)

display all >>

Presentations 【 Display / hide 】

Presentations 【 Display / hide 】

• ポサコナゾールの血清タンパク質への結合特性の解析.

  岡本侑子、田口和明、五十嵐裕貴、榎木裕紀、松元一明.

  [Domestic presentation]  第35回日本医療薬学会年会 (兵庫県) , 

  2025.11

  , 

  Poster presentation

• CREによる肺炎マウスモデルを用いたNAC/CFPM併用療法時の目標T>MICi値.

  水上雄貴、岡本侑子、五十嵐裕貴、榎木裕紀、田口和明、池上眞太郎、鈴木健太、高橋実秀、松元一明.

  [Domestic presentation]  第35回日本医療薬学会年会 (兵庫県) , 

  2025.11

  , 

  Oral presentation (general)

• バンコマイシンの2回目TDMにおける2点採血の必要性.

  鈴木絢子、藤原久登、山口史博、吉田博昭、田中宏明、八木祐助、浜田幸宏、石郷友之、藤居賢、南雲史雄、佐村優、千葉博暁、海老原文哉、丸山拓実、詫間章俊、小松敏彰、冨澤淳、西圭史、五十嵐裕貴、榎木裕紀、松元一明.

  [Domestic presentation]  第35回日本医療薬学会年会 (兵庫県) , 

  2025.11

  , 

  Oral presentation (general)

• 腎機能低下症例は2点採血でバンコマイシンのAUCを適切に調整することでAKIリスクを上昇させない.

  石郷友之、鈴木絢子、藤居賢、伊部裕太、福土将秀、吉田博昭、田中宏明、海老原文哉、丸山拓実、八木祐助、佐村優、南雲史雄、小松敏彰、冨澤淳、詫間章俊、千葉博暁、五十嵐裕貴、榎木裕紀、浜田幸宏、西圭史、松元一明.

  [Domestic presentation]  第35回日本医療薬学会年会 (兵庫県) , 

  2025.11

  , 

  Oral presentation (general)

• シンポジウム3：薬剤師と真菌感染症「抗真菌薬の適正使用のためのガイドラインの潮流」

  松元一明.

  [Domestic presentation]  第69回日本医真菌学会総会・学術集会 (高知県) , 

  2025.10

  , 

  Symposium, workshop panel (nominated)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Research Projects of Competitive Funds, etc. 【 Display / hide 】

• 新規肺MABC症治療薬の開発と革新的非臨床PK/PD評価法の構築

  2024.04

  -

  2028.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

• 薬剤耐性淋菌・緑膿菌に有効な新規抗菌剤の開発

  2023.08

  -

  2024.03

  国立研究開発法人日本医療研究開発機構（AMED）, 新興・再興感染症に対する革新的医薬品等開発推進研究事業, Joint research, Coinvestigator(s)

• ホローファイバー感染モデルを用いたカルバペネム耐性菌感染症の抗菌薬併用療法に関する橋渡し研究

  2022.04

  -

  2025.03

  国立研究開発法人国立国際医療研究センター, 国際医療研究開発事業, Joint research, Coinvestigator(s)

• マウス肺感染モデルを用いたOP0595の臨床有効性予測

  2022.01

  -

  2024.03

  Meiji Seikaファルマ株式会社, Commissioned ｒesearch, Principal investigator

• Investigation of the effectiveness of imeglimin as a potential therapeutic agent for sarcopenia

  2021.09

  -

  2023.08

  大日本住友製薬株式会社, Commissioned ｒesearch, Principal investigator

display all >>

Intellectual Property Rights, etc. 【 Display / hide 】

Intellectual Property Rights, etc. 【 Display / hide 】

• メトヘモグロビン小胞体を有効成分として含む医薬およびその使用

  Date applied： 特願2020-144044  2020.08 

  Patent, Joint

Awards 【 Display / hide 】

Awards 【 Display / hide 】

• 第35回日本医療薬学会年会優秀演題賞

  石郷友之、鈴木絢子、藤居賢、伊部裕太、福土将秀、吉田博昭、田中宏明、海老原文哉、丸山拓実、八木祐助、佐村優、南雲史雄、小松敏彰、冨澤淳、詫間章俊、千葉博暁、五十嵐裕貴、榎木裕紀、浜田幸宏、西圭史、松元一明, 2025.11, 腎機能低下症例は2点採血でバンコマイシンのAUCを適切に調整することでAKIリスクを上昇させない

• 第17回日本化学療法学会東日本支部 支部奨励賞（基礎）

  鈴木健太、島村莉奈、吉川万衣子、宇山杏奈、林侑孝、五十嵐裕貴、榎木裕紀、西村知泰、松元一明, 2025.09, Hollow Fiber Infection Modelを用いた肺MAC症に対する標準治療の有効性評価

• 第8回フレッシャーズ・カンファランス優秀演題発表賞

  島村莉奈, 西村知泰, 吉川万衣子, 三澤可奈, 矢野大和, 榎木裕紀, 五十嵐裕貴, 長谷川直樹, 南宮湖, 松元一明, 2025.06, 抗菌薬投与が引き起こすMycobacterium abscessusの細胞壁脂質とコロニー形態の変化

• 日本薬学会第145年会 学生優秀発表賞受賞（口頭発表）

  三原貴之、松本ゆうり、坪内愛佑、池上眞太郎、高橋実秀、中林花音、西本直人、水上雄貴、村石琢真、榎木裕紀、田口和明、松元一明, 2025.04, 肺炎球菌感染症に対する13価、23価肺炎球菌ワクチンの併用と23価肺炎球菌ワクチン単剤接種の有効性および安全性比較：システマティックレビュー＆メタ解析

• 日本薬学会第145年会 学生優秀発表賞受賞（口頭発表）

  杉本唯衣, 佐々木崚介, 富永真由, 平井柳佳, 三原貴之, 榎木裕紀, 田口和明, 松元一明, 2025.04, 腸球菌による感染性心内膜炎に対するβラクタム系薬2剤併用とβラクタム系薬/アミノグリコシド系薬併用の有効性及び安全性比較：システマティックレビュー, メタ解析

display all >>

Courses Taught 【 Display / hide 】

Courses Taught 【 Display / hide 】

• PHARMACEUTICAL-ENGLISH SEMINAR

  2026

• PRE-CLINICAL TRAINING IN PRESCRIPTION PROCESSING FOR HOSPITAL & COMMUNITY PHARMACY

  2026

• BACHELOR'S THESIS

  2026

• ENGLISH EXERCISES FOR PHARMACEUTICAL SCIENCES

  2026

• CLINICAL PHARMACOLOGY AND PHARMACEUTICS

  2026

display all >>

Social Activities 【 Display / hide 】

Social Activities 【 Display / hide 】

• 薬剤耐性菌感染症治療薬の臨床評価に関する報告書

  独立行政法人医薬品医療機器総合機構

  2019.08

  -

  2020.10

Memberships in Academic Societies 【 Display / hide 】

Memberships in Academic Societies 【 Display / hide 】

• 日本医真菌学会, 

  2019.02

  -

  Present

• 日本DDS学会, 

  2018.05

  -

  Present

• 日本臨床微生物学会, 

  2018.03

  -

  Present

• 日本老年薬学会　理事・評議員, 

  2016.04

  -

  Present

• 日本薬剤学会　代議員, 

  2015.12

  -

  Present

display all >>